华康生物医学(08622)拟折让约19.23%配售最多8200万股新股份
华康生物医学(08622)发布公告，于2024年1月8日，该公司与配售代理订立配售协议，配售代理同意为及代表公司按每股配售股份0.105港元的价格尽力向不少于六名独立承配人配售最多8200万股新股份。
配售股份的最高数目为8200万股，占公司经配售事项扩大的全部已发行股本的约16.38%，配售价较1月8日收市报价每股0.130港元折让约19.23%。配售事项的所得款项净额约为838万港元(假设配售股份获悉数配售及扣除一切有关开支后)，将用于一般营运资金。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.